OLEMA PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.8 USD | -4.45% |
|
-9.01% | -37.35% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,840 | 372 | 98.27 | 766.3 | 514.8 | - | - |
| Enterprise Value (EV) 1 | 1,840 | 372 | 98.27 | 766.3 | 432.6 | 386.1 | 397.5 |
| P/E ratio | -14.1 x | -5.2 x | -0.94 x | -6.56 x | -3.83 x | -3.53 x | -3.32 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 67.3 x |
| EV / Revenue | - | - | - | - | - | - | 52 x |
| EV / EBITDA | -85.5 x | -5.22 x | -0.92 x | -7.33 x | -3.21 x | -2.22 x | -1.84 x |
| EV / FCF | -92.4 x | -7.12 x | -1.19 x | -9.15 x | -5.38 x | -2.88 x | -2.65 x |
| FCF Yield | -1.08% | -14% | -83.9% | -10.9% | -18.6% | -34.7% | -37.7% |
| Price to Book | - | - | 0.5 x | 3.04 x | 2.17 x | 1.64 x | - |
| Nbr of stocks (in thousands) | 38,274 | 39,745 | 40,110 | 54,622 | 55,893 | - | - |
| Reference price 2 | 48.08 | 9.360 | 2.450 | 14.03 | 9.210 | 9.210 | 9.210 |
| Announcement Date | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 7.647 |
| EBITDA 1 | - | -21.52 | -71.33 | -106.6 | -104.6 | -134.8 | -174.2 | -216.2 |
| EBIT 1 | - | -21.53 | -71.49 | -107 | -105 | -138.5 | -168.6 | -187.4 |
| Operating Margin | - | - | - | - | - | - | - | -2,450.66% |
| Earnings before Tax (EBT) 1 | - | -22.12 | -71.1 | -104.8 | -96.66 | -134.1 | -166.5 | -182 |
| Net income 1 | -4.316 | -23.99 | -71.1 | -104.8 | -96.66 | -134 | -166.4 | -182 |
| Net margin | - | - | - | - | - | - | - | -2,380.29% |
| EPS 2 | -0.6000 | -3.420 | -1.800 | -2.620 | -2.140 | -2.403 | -2.606 | -2.773 |
| Free Cash Flow 1 | - | -19.92 | -52.26 | -82.43 | -83.73 | -80.33 | -134 | -150 |
| FCF margin | - | - | - | - | - | - | - | -1,961.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/30/20 | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -21.68 | -23.17 | -33.21 | -23.13 | -27.12 | -29.5 | -21.5 | -23.25 | -30.33 | -34.25 | -33.98 | -35.87 | -39.31 | - | - |
| EBIT 1 | -21.76 | -23.25 | -33.29 | -23.22 | -27.22 | -29.6 | -21.6 | -23.34 | -30.42 | -34.34 | -33.27 | -34.94 | -37 | -34.14 | -38 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.64 | -23.03 | -32.86 | -22.72 | -26.18 | -28.29 | -20.1 | -21.5 | -26.77 | -30.97 | -32.59 | -34.21 | -36.67 | -35 | -38 |
| Net income 1 | -21.64 | -23.03 | -32.86 | -22.72 | -26.18 | -28.29 | -20.1 | -21.5 | -26.77 | -30.97 | -32.59 | -34.21 | -36.67 | -35 | -38 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5400 | -0.5800 | -0.8200 | -0.5700 | -0.6500 | -0.7000 | -0.4900 | -0.4800 | -0.4900 | -0.5600 | -0.5847 | -0.6040 | -0.6498 | -0.6000 | -0.6500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/11/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 82.2 | 129 | 117 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.9 | -52.3 | -82.4 | -83.7 | -80.3 | -134 | -150 |
| ROE (net income / shareholders' equity) | - | -14.6% | -22.8% | -43.5% | -42.8% | -63.8% | -78.7% | -73.6% |
| ROA (Net income/ Total Assets) | - | -14% | -22.3% | -41% | -39.2% | -49.2% | -48.2% | - |
| Assets 1 | - | 171.4 | 319.3 | 255.8 | 246.3 | 272.5 | 345.2 | - |
| Book Value Per Share 2 | - | - | - | 4.900 | 4.620 | 4.250 | 5.620 | - |
| Cash Flow per Share | - | - | - | -2.050 | - | - | - | - |
| Capex 1 | - | 0.06 | 1.58 | 0.36 | - | 1 | 1.33 | 2 |
| Capex / Sales | - | - | - | - | - | - | - | 26.16% |
| Announcement Date | 10/30/20 | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.21
USD
Average target price
26.56
USD
Spread / Average Target
+188.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.35% | 515M | |
| +65.17% | 62.59B | |
| -1.48% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.40% | 26.21B | |
| -21.78% | 19.09B | |
| +4.90% | 13.08B | |
| +25.47% | 12.26B | |
| +28.61% | 12.05B |
- Stock Market
- Equities
- OLMA Stock
- Financials Olema Pharmaceuticals, Inc.
